Skip to main content
Published locations for Atezolizumab plus bevacizumab offers a better prognosis than lenvatinib in unresectable HCC
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
Atezolizumab plus bevacizumab offers a better prognosis than lenvatinib in unresectable HCC
User login
Username
Password
Reset your password
/content/atezolizumab-plus-bevacizumab-offers-better-prognosis-lenvatinib-unresectable-hcc-0
/gihepnews/article/255720/hepatocellular-carcinoma/atezolizumab-plus-bevacizumab-offers-better